Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
FEMS Immunol Med Microbiol ; 33(2): 89-99, 2002 Jun 03.
Artigo em Inglês | MEDLINE | ID: mdl-12052563

RESUMO

The outer membrane protein F gene (oprF) of Pseudomonas aeruginosa was recently shown by us to protect mice from P. aeruginosa chronic pulmonary infection when used as a DNA vaccine administered by three biolistic (gene gun) intradermal inoculations given at 2-week intervals. In the present study, we used two different strategies to improve the protective efficacy of the DNA vaccine. In the first strategy, mice were primed with two biolistic intradermal inoculations with the oprF vaccine and then were given a final intramuscular booster immunization containing either a synthetic peptide-keyhole limpet hemocyanin (KLH) conjugate or a chimeric influenza virus. Both the synthetic peptide conjugate and the chimeric virus contained peptide 10, a previously identified immunoprotective epitope of protein F. The second strategy involved the addition of a second outer membrane protein to the vaccine. DNA encoding a fusion protein comprised of the C-terminal half of protein F fused to OprI was administered by three biolistic intradermal inoculations. Challenge with P. aeruginosa in a chronic pulmonary infection model demonstrated that boosting with the chimeric virus (but not with peptide-KLH) or adding oprI to the DNA vaccine significantly enhanced protection as compared to that afforded by the oprF vaccine given alone. Thus, both strategies appear to augment the protection afforded by an oprF-only DNA vaccine.


Assuntos
Anticorpos Antibacterianos/sangue , Vacinas Bacterianas/imunologia , Pneumopatias/prevenção & controle , Porinas/imunologia , Pseudomonas aeruginosa/imunologia , Vacinas de DNA/imunologia , Animais , Vacinas Bacterianas/administração & dosagem , Doença Crônica , Modelos Animais de Doenças , Feminino , Hemocianinas/genética , Hemocianinas/imunologia , Humanos , Esquemas de Imunização , Imunização Secundária , Pneumopatias/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Opsonizantes/metabolismo , Orthomyxoviridae/genética , Orthomyxoviridae/imunologia , Orthomyxoviridae/metabolismo , Peptídeos/síntese química , Peptídeos/genética , Peptídeos/imunologia , Porinas/química , Porinas/genética , Porinas/metabolismo , Infecções por Pseudomonas/microbiologia , Infecções por Pseudomonas/prevenção & controle , Pseudomonas aeruginosa/genética , Proteínas Recombinantes de Fusão/imunologia , Vacinas de DNA/administração & dosagem
2.
Microbiology (Reading) ; 145 ( Pt 8): 2061-2067, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10463172

RESUMO

The plant virus cowpea mosaic virus (CPMV) is an efficient carrier of foreign peptides for the generation of strong humoral immune responses. Peptides derived from both viruses and bacteria are strongly immunogenic when displayed on the surface of CPMV and elicit high titres of peptide-specific antibody. However, the protective effects of antibodies generated using bacterial epitopes in this system have yet to be demonstrated. In this study the ability of chimaeric virus particles (CVPs) to afford protection against bacterial infection was assessed. Immunization of outbred mice with CPMV expressing a peptide derived from outer-membrane protein F of Pseudomonas aeruginosa (CPMV-PAE5) generated high titres of P. aeruginosa-specific IgG that opsonized the bacteria for phagocytosis by human neutrophils and afforded protection upon challenge with two different immunotypes of P. aeruginosa in a model of chronic pulmonary infection. When examined 8 d after challenge, CVP-immunized mice had fewer severe lung lesions and fewer bacteria in their lungs compared to mice immunized with wild-type virus. Different levels of protection were seen with CPMV-PAE5 when Freund's or alum adjuvants were used. These studies highlight the ability of CVPs to generate protective immunity against infectious disease agents.


Assuntos
Vacinas Bacterianas/imunologia , Comovirus/genética , Infecções por Pseudomonas/prevenção & controle , Pseudomonas aeruginosa/imunologia , Vacinas Sintéticas/imunologia , Animais , Anticorpos Antibacterianos/sangue , Especificidade de Anticorpos , Proteínas da Membrana Bacteriana Externa/química , Vacinas Bacterianas/administração & dosagem , Comovirus/imunologia , Feminino , Humanos , Pulmão/patologia , Pneumopatias/microbiologia , Camundongos , Camundongos Endogâmicos ICR , Proteínas Opsonizantes/imunologia , Peptídeos/genética , Peptídeos/imunologia , Pseudomonas aeruginosa/química , Proteínas Recombinantes de Fusão/administração & dosagem , Proteínas Recombinantes de Fusão/imunologia , Vacinação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA